Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

Phase 2, Randomized, Patient- and Rater-blinded Single-site Trial Evaluating Safety and Efficacy of Efgartigimod in Patients With Guillain-Barré Syndrome.

The goal of this clinical trial is to evaluate the safety and effectiveness of Efgartigimod in patients with Guillain-Barre syndrome (GBS). The main questions it aims to answer are:

• Is Efgartigimod a safe treatment option for GBS patients?
• Does treatment with Efgartigimod improve patient outcomes?

In addition to standard-of-care procedures and assessments, participants will:

• Undergo seven blood draws during hospitalization and in four follow-up study visits to evaluate the concentration of neurofilament light chain, a protein that is elevated in patients with Guillain-Barré syndrome. The presence of neurofilament light chain is believed to be indicative of damage to the nervous system, with higher levels resulting from greater damage.
• Complete the Columbia Suicide Severity Rating Scale (C-SSRS) to monitor any suicidal ideation or behaviors during the course of the study.

Study Overview

• Status: Withdrawn
• Conditions: Guillain-Barre Syndrome
• Intervention / Treatment: Drug: Efgartigimod Alfa-Fcab; Drug: Intravenous Immunoglobulin (IVIg)

Detailed Description

The following procedures/assessments are standard-of-care for Guillain-Barré syndrome. They will not be performed solely for research purposes in this study, but the study team will use select results from them to draw conclusions related to this research:

• The study doctor or study staff will ask you about your medical history and any changes to your medications
• You will have a physical examination
• Your vital signs, including blood pressure, pulse rate, breathing rate, body temperature, and weight will be measured
• You will have an electrocardiogram (ECG)
• Pulmonary function testing, including forced vital capacity (FVC), maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) will be performed
• Blood samples will be drawn to evaluate disease progression and safety/efficacy of treatment
• You will undergo a lumbar puncture, commonly referred to as a spinal tap, to collect cerebrospinal fluid (CSF) for analysis
• Nerve conduction studies (NCS) will be performed
• Outcome assessments including the GBS Disability Scale (GBS-DS), MRC Sum Score, and Inflammatory Rasch-built Overall Disability Scale (I-RODS) will be performed

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Hospital of University of Pennsylvania

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or female, aged 18 years or older
• Have a diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for Guillain-Barré Syndrome
• Onset of GBS-related weakness ≤14 days prior to infusion
• GBS-DS score of 3, 4, or 5

Exclusion Criteria:

• Pregnant and lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing. Women of childbearing potential should have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline prior to administration of IMP. Note: Women of childbearing potential should use a highly effective method of contraception (i.e., pregnancy rate of less than 1% per year) during the trial and for 90 days after the last administration of the IMP. They must be on a stable regimen, for at least 1 month, of combined estrogen and progestogen hormonal contraception with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or agree upon continuous abstinence from heterosexual sexual contact.
• Male patients who are sexually active and do not intend to use effective methods of contraception (as mentioned above) during the trial or within 90 days after the last dosing or male patients who plan to donate sperm during the trial or within 90 days after the last dosing. Note: Sterilized male patients who have had vasectomy with documented aspermia post-procedure, or male patients who have a partner of non-childbearing potential, can be included.
• GBS DS of 2 or less.
• Patients with any known severe bacterial, viral or fungal infection or any major episode of infection that required hospitalization or injectable antimicrobial therapy in the last 8 weeks prior to Screening.
• Patients with more than 14 days after onset of symptoms.
• Patients with known IgG deficiency.
• Patients with recurrent GBS.
• Use of investigational drug within 3 months or 5 half-lives of the drug (whichever is longer) prior to Screening.
• Patients who have a history of malignancy, including malignant thymoma, or myeloproliferative or lymphoproliferative disorders, unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 3 years before Screening. Patients with completely excised non-melanoma skin cancer (such as basal cell carcinoma or squamous cell carcinoma) or cervical carcinoma in situ would be permitted at any time.
• Patients with clinical evidence of other significant serious disease or patients who underwent a recent major surgery, which could confound the results of the trial or put the patient at undue risk. Patients with renal/hepatic function impairment can be included.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Efgartigimod Alfa-Fcab; 20mg/kg of Intravenous efgartigimod on days 1 and 5, with normal saline administered as placebo on days 2-4	Drug: Efgartigimod Alfa-Fcab; Efgartigimod is an anti-neonatal Fc receptor (FcRn) immunoglobulin G1 Fc fragment. The FcRn plans a critical role in extending the half-life of IgGs by rescuing them from lysosomal degradation. Antibodies that bind and subsequently block the FcRn with high affinity result in IgGs being degraded more rapidly instead of salvaged. This approach has been shown to be beneficial in the antibody-mediated disorder myasthenia gravis.; Other Names: Vyvgart
Active Comparator: Intravenous Immunoglobulin (IVIg); 0.4g/kg of IVIg daily for 5 days	Drug: Intravenous Immunoglobulin (IVIg); IVIg is the standard-of-care treatment for GBS. Brand of IVIG used may vary per institutional standards; Other Names: Standard of Care IVIG

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Guillain-Barre Syndrome Disability Scale (GBS-DS)	Scoring system that assesses the functional status of GBS subjects. Scores range from 0 to 6, with higher scores indicating a worse outcome.	Week 4
Number and seriousness in adverse events in the studied population	Safety monitoring	Through study completion, an average of 3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Guillain-Barre Syndrome Disability Scale (GBS-DS)	Scoring system that assesses the functional status of GBS subjects. Scores range from 0 to 6, with higher scores indicating a worse outcome.	12 and 24 weeks
MRC Sum Score	Quantifies strength, with a higher score indicating more strength.	12 and 24 weeks
Inflammatory Rasch-Built Overall Disability Scale (I-RODS)	Functional outcome assessment. Scores range from 0 to 48, with higher scores indicating a better outcome.	4, 8, 12, and 24 weeks
Number of Days on Respirator	as noted in the title	4, 8, 12, and 24 weeks
Number of days in an intensive care unit	as noted in the title	4, 8, 12, and 24 weeks
Number of days to hospital discharge	as noted in the title	4, 8, 12, and 24 weeks
Mortality	Change in vital status	4, 8, 12, and 24 weeks
Percentage of patients with secondary deterioration due to treatment-related fluctuations (TRF)	as noted in the title	4, 8, 12, and 24 weeks
Adverse Events	occurrence of adverse events	4, 8, 12, and 24 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Study effect of Efgartigimod on IgG levels	Blood sample to analyze change in IgG levels	change from baseline to 4 weeks and 24 weeks

Collaborators and Investigators

• Sponsor: Chafic Karam
• Collaborators: argenx
• Investigators: Principal Investigator: Chafic Karam, MD, Staff Physician and Associate Professor of Clinical Neurology; Study Director: Colin Quinn, MD, Staff Physician and Associate Professor of Clinical Neurology

Study record dates

Study Major Dates

• Study Start (Actual): September 10, 2024
• Primary Completion (Actual): January 19, 2026
• Study Completion (Estimated): February 20, 2026

Study Registration Dates

• First Submitted: January 5, 2023
• First Submitted That Met QC Criteria: January 17, 2023
• First Posted (Actual): January 27, 2023

Study Record Updates

• Last Update Posted (Actual): March 12, 2026
• Last Update Submitted That Met QC Criteria: March 10, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Post-Infectious Disorders; Nervous System Diseases; Pathologic Processes; Neuromuscular Diseases; Chronic Disease; Disease Attributes; Autoimmune Diseases; Immune System Diseases; Peripheral Nervous System Diseases; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Polyneuropathies; Polyradiculoneuropathy; Pathological Conditions, Signs and Symptoms; Guillain-Barre Syndrome; Amino Acids, Peptides, and Proteins; Proteins; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Serum Globulins; Globulins; Immunoglobulin Isotypes; Immunoglobulin G; Immunoglobulins, Intravenous; efgartigimod alfa
• Other Study ID Numbers: 852292

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No